$BNCM / $DELEX is set to launch Receptal in the U.S. by February 2025, bringing Amsino’s proven closed-suction tech to hospitals nationwide.
Execution > promises — and this is just the beginning.
#OTC #Investing #HealthcareInnovation #OTC #MedTech #Receptal #Amsino #BNCM #DELEX #GrowthMode #Feb2025

The U.S. medical market rewards one thing: solutions that work. Receptal is already a proven closed-suction system globally and now it enters a $7B+ U.S. hospital suction & fluid management market.
#BNCM #DELEX #HealthcareInnovation #OTC #MedTech #Receptal #Amsino #BNCM #DELEX #GrowthMode #Feb2025

parkingg my car into the someone's yard and plugging my 120V charger into some rando"s outside receptal

Receptal isn’t entering the U.S. market as a rookie it’s a globally used system backed by years of hospital adoption. The difference now is scale. DELEX is positioning itself to supply a solution the market already trusts.

U.S. hospitals perform millions of procedures yearly requiring safe closed-suction systems. That’s not speculation that’s consistent, unavoidable demand. Receptal steps directly into that stream.

Danske Bank om Wegovy-pille: Novo har brug for højere receptal for at nå i mål i år Læs mere👇 #dkbiz

The $7B+ market isn’t theoretical. It’s built on recurring demand from surgeries, emergency care, and routine hospital procedures. Receptal positions DELEX at the center of a segment that never stops operating.